Back to Authors

Qiu, Lugui

0000-0002-8752-0644

Mayo Clinic

Chinese Academy of Medical Sciences & Peking Union Medical College

Citations 3

Longitudinal genetically detectable minimal residual disease by fluorescence in situ hybridization confers a poor prognosis in myeloma
Cui, Jian , Yu, Tengteng , Lv, Rui , Liu, Jiahui , Fan, Huishou , Xu, Jingyu , Du, Chenxing , Sui, Weiwei, Xu, Yan , Qiu, Lugui , An, Gang , Ho, Matthew , Cui, Jian , Yan, Wenqiang , Deng, Shuhui , Ho, Matthew , Anderson, Kenneth C. , Dong, Xifeng , Qiu, Lugui

Therapeutic Advances in Medical Oncology | January 20, 2024 | Volume: 16 | Issue: No issue available | Pages: No page available

10.1177/17588359231221340 Get It

Background: Deeper depth of response (DpR) after induction therapy, especially gain of negative minimal residual disease (MRD), has been linked to prolonged survival in multiple myeloma (MM). However, flow-MRD examination focuses on the numbers but not on the biological characteristics of residual plasma cells (PCs). Objectives: To explore whether the genetic features of residual tumor cells affect the survival time of patients with MM. Design: A retrospective cohort study. Methods: We investigated the clonality of cytogenetic abnormalities (CAs) of the residual PCs using interphase fluorescence in situ hybridization (iFISH) in the National Longitudinal Cohort of Hematological Diseases in China (NCT04645199). Here, a longitudinal cohort of 269 patients with patient-paired diagnostic and post-induction iFISH results was analyzed. Results: Persistent CAs after induction therapy were detected in about half of the patients (118/269, 43%), and patients with undetectable CAs showed significantly improved survival compared with those with genetically detectable MRD [median progression-free survival (mPFS): 59.7 versus 35.7 months, p < 0.001; median overall survival (mOS): 97.1 versus 68.8 months, p = 0.011]. In addition, different patterns of therapy-induced clonal evolution were observed by comparing the clonal structure of residual PCs with paired baseline samples. Patients who maintained at a high risk during follow-up had the worst survival (mPFS: 30.5 months; mOS: 54.4 months), while those who returned to lower risk or had iFISH− at both time points had the best survival (mPFS: 62.0 months, mOS: not reached). Conclusion: These findings highlighted the prognostic value of genetic testing in residual tumor cells, which may provide a deep understanding of clonal evolution and guide clinical therapeutic strategies.
FIRST study: Updated overall survival (OS) in stem cell transplant (SCT)-ineligible newly diagnosed multiple myeloma (NDMM) patients (pts) treated with continuous lenalidomide plus low-dose dexamethasone (Rd) vs melphalan, prednisone, and thalidomide (MPT)
Hulin, Cyrille , Belch, Andrew R. , Reece, Donna , Catalano, John, Qiu, Lugui , Schots, Rik , Marek, Jennifer, Chen, Guang , Ervin‐Haynes, Annette, Facon, Thierry T.F. , Dimopoulos, Meletios Α. , Pinto, Antonio , Ludwig, Heinz , Bahlis, Nizar Jacques , Cavo, Michèle , Moreau, Philippe , Qiu, Lugui , LeBlanc, Richard , Rajkumar, S. Vincent

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8524-8524

10.1200/jco.2015.33.15_suppl.8524 Get It

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Catalano, John, Belch, Andrew , Cavo, Michèle , Pinto, Antonello, Banos, Anne , Tiab, Mourad, Delforge, Michel , Cavenagh, Jamie, Lee, Je‐Jung , Chen, Christine , Oriol, Albert , Rubia, Javier de la , White, Darrell , Binder, Daniel, Moreau, Philippe , Perrot, Aurore , Arnulf, Bertrand , Qiu, Lugui , Roussel, Murielle , Boyle, Eileen M. , Manier, Salomon , Mohty, Mohamad , Avet‐Loiseau, Hervé , Leleu, Xavier , Ervin‐Haynes, Annette, Chen, Guang , Houck, Vanessa, Benboubker, Lotfi , Hulin, Cyrille , Pinto, Antonio , Moreau, Philippe , Perrot, Aurore , Boyle, Eileen M , Facon, Thierry T.F. , Dimopoulos, Meletios Α. , Dispenzieri, Angela , Pinto, Antonello, Weisel, Katja C , Ludwig, Heinz , Bahlis, Nizar Jacques , Geraldes, Catarina , Lu, Jin Ping , Anderson, Kenneth C. , Attal, Michel , Qiu, Lugui , Roussel, Murielle , Pinto, Antonio , Oriol, Albert , Mohty, Mohamad

Blood | November 17, 2017 | Volume: 131 | Issue: 3 | Pages: 301-310

10.1182/blood-2017-07-795047 Get It

Key Points Rd continuous significantly extended OS compared with MPT and resulted in comparable OS to that with Rd18 in patients with multiple myeloma. Patients achieving complete or very good partial response with Rd benefited greatly from continuous vs fixed treatment in terms of PFS.